If you have been reading about Beta-lactoglobulin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Compared with whey protein concentrate or isolate, hydrolysate has a smaller average peptide size and a higher proportion of low-molecular-weight fractions. This change can affect solubility, viscosity, osmolality, taste, and foam formation. Some hydrolysates are bitter because hydrophobic peptides are exposed during cleavage. The term hydrolysate does not indicate a guaranteed peptide profile; two products with the same reported hydrolysis value can differ in peptide sequence and residual intact protein. Commercial specifications usually state protein content, moisture, ash, fat, and microbiology, while peptide distribution may be reported as a range.
Whey protein hydrolysate appears in infant formula, sports nutrition, and clinical nutrition. In infant formula, extensively hydrolyzed products are used when a reduced allergenicity is desired, though not all hydrolysates are hypoallergenic. In sports products, the ingredient is marketed for rapid amino acid delivery, but the practical advantage over intact whey protein remains debated. Research often compares hydrolysate with isolate or concentrate for absorption kinetics, muscle protein synthesis, and gastrointestinal tolerance. Regulatory categories differ by country, and label terms such as partially hydrolyzed or extensively hydrolyzed are defined in some jurisdictions but not others.
Quality control for whey protein hydrolysate begins with verifying protein content, moisture, ash, and fat using standard food analysis methods. Total nitrogen by Kjeldahl or Dumas combustion gives an estimate of protein, often calculated with a dairy-specific conversion factor. Amino acid analysis after acid hydrolysis quantifies individual residues but destroys tryptophan and may convert glutamine and asparagine. The extent of peptide bond cleavage is usually estimated by measuring free amino groups, soluble nitrogen, or trichloroacetic acid-soluble peptides. These tests are operationally defined and can give different results across laboratories.
Peptide size distribution is central to product characterization because biological and functional effects often depend on molecular weight. Size-exclusion chromatography, reversed-phase high-performance liquid chromatography, and capillary electrophoresis can separate peptides by size or hydrophobicity. Mass spectrometry provides sequence-level information and can detect marker peptides, though it is less common for routine lot release. For allergen control, enzyme-linked immunosorbent assays estimate residual intact protein or specific milk proteins, but results depend on antibody recognition and may not detect small peptides. No single method captures the full composition.
Stability and storage practices affect measured quality over time. Hydrolysate powders are hygroscopic and can absorb moisture, leading to caking, Maillard browning, and reduced solubility. Cool, dry storage in sealed containers limits these changes, while high humidity and warm temperatures accelerate them. Microbiological testing for total aerobic counts, yeasts, molds, and specified pathogens is typical for food ingredients. Regulatory status varies by country; in many jurisdictions hydrolyzed whey protein is regulated as a food ingredient rather than a drug, and claims about reduced allergenicity require specific substantiation.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to light tan powder | Color can vary with hydrolysis and drying |
| Protein content | 70–90% dry basis | Lower if ash, lactose, or moisture remain |
| Degree of hydrolysis | Typically 5–35% | Partially and extensively hydrolyzed types differ |
| Solubility | Water-soluble | High across common food pH ranges, though peptide dependent |
| Common synonyms | Whey hydrolysate; hydrolyzed whey protein | Sometimes abbreviated WPH on labels |
Whey protein hydrolysate is a dairy ingredient produced when whey proteins are treated with proteolytic enzymes or, less commonly, acid or heat under controlled conditions. The treatment cleaves peptide bonds and yields shorter peptide chains than those found in intact whey protein. The starting material is usually sweet whey or acid whey from cheese manufacture, concentrated by membrane filtration before hydrolysis. The resulting ingredient retains many amino acids from the original protein but differs in molecular size, solubility, and taste profile.
The parent whey proteins include beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulins, and glycomacropeptide, depending on the whey source. Hydrolysis does not remove these sequences; it fragments them into peptides of varying length. The peptide distribution depends on the enzyme specificity, reaction time, temperature, pH, and enzyme-to-substrate ratio. Because the mixture is heterogeneous, a single molecular weight cannot describe the product. Instead, laboratories report a distribution, often spanning from a few hundred to several thousand daltons.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
Quality control checks identity, composition, and contaminants. Moisture, ash, fat, and carbohydrate are measured by standard methods, and microbiological limits are set for total counts, coliforms, and specific pathogens. Heavy metals and pesticide residues may be monitored depending on market requirements. Adulteration with intact whey protein or individual amino acids is possible, so peptide fingerprints and free amino acid profiles can help verify authenticity. Regulatory frameworks vary: some countries treat hydrolyzed whey as a conventional dairy ingredient, while infant formula uses face additional compositional rules. Which marker peptides best confirm source and processing remains an open analytical question.
Storage stability depends on moisture, temperature, and packaging. Dry powders with low water activity resist microbial growth, but they can still absorb water, develop off-colors through Maillard reactions, or oxidize residual lipids. Sealed containers kept in a cool, dry place are standard. Stability studies typically monitor moisture, solubility, color, peptide size, and microbial counts over months. Established practice favors low humidity and moderate temperatures. How brief excursions above recommended conditions affect peptide profiles and sensory qualities is less predictable and may depend on the specific product matrix.
The Edman degradation is an alternative method for peptide sequencing that cleaves amino acid residues from the N-terminus of a peptide. In 1950 Edman designed a reaction with phenylthiocyanate (the idea for which was borrowed from a 1927 study by Bergmann, Kann and Miekeley ) to give phenylthiocarbamyl peptides followed by hydrolysis under relatively mild conditions to cleave N-terminal amino acid as phenylthiohydantoin. Phenylthiohydantoin is stable enough to undergo various sequencing procedures such as those which involve chromatography and mass spectrometry. This was an improvement on an earlier method proposed by Abderhalden and Brockmann in 1930 that demonstrated N-terminal amino acid conversion to a hydantoin under stronger hydrolytic conditions, where some cleavage of the residual peptide proved problematic. The primary advantage the Edman degradation has over the Bergmann degradation is the ease with which the residual peptide can re-enter the process due to retention of its structure throughout sequential cleaving. Repetition of the Bergmann degradation is presumably not as straightforward, as the remaining peptide is in amide form.
In plants, nitrogen is first assimilated into organic compounds in the form of glutamate, formed from alpha-ketoglutarate and ammonia in the mitochondrion. For other amino acids, plants use transaminases to move the amino group from glutamate to another alpha-keto acid. For example, aspartate aminotransferase converts glutamate and oxaloacetate to alpha-ketoglutarate and aspartate. Other organisms use transaminases for amino acid synthesis, too. Nonstandard amino acids are usually formed through modifications to standard amino acids. For example, homocysteine is formed through the transsulfuration pathway or by the demethylation of methionine via the intermediate metabolite S-adenosylmethionine, while hydroxyproline is made by a post translational modification of proline. Microorganisms and plants synthesize many uncommon amino acids. For example, some microbes make 2-aminoisobutyric acid and lanthionine, which is a sulfide-bridged derivative of alanine. Both of these amino acids are found in peptidic lantibiotics such as alamethicin. However, in plants, 1-aminocyclopropane-1-carboxylic acid is a small disubstituted cyclic amino acid that is an intermediate in the production of the plant hormone ethylene.
Both the thyroid and adrenal glands can be infiltrated. It is estimated that 10–20% of people with amyloidosis have hypothyroidism. Adrenal infiltration may be harder to appreciate given that its symptoms of orthostatic hypotension and low blood sodium concentration may be attributed to autonomic neuropathy and heart failure. "Amyloid deposits occur in the pancreas of people who also have diabetes mellitus, although it is not known if this is functionally important. The major component of pancreatic amyloid is a 37-amino acid residue peptide known as islet amyloid polypeptide or 'amylin.' This is stored with insulin in secretory granules in [beta] cells and is co secreted with insulin." (Rang and Dale's Pharmacology, 2015.)
Sources: en.wikipedia.org
On-line mass spectrometry was develop to solve some of the limitations and problem that develop from off-line analysis, such as evaporation and chemical reactions of particles in the filters during long analysis time. On-line Mass spectrometry solves these problems through the collection and analysis of aerosol particles in real time. On-line instruments are very portable and allow for spatial variability to be examined. These portable instruments can be put on many different platforms such as boats, planes, and mobile platforms (e.g. car trailers). An example of this is in the picture at the beginning with the instrumentation attached to an aircraft. Like off-line, on-line mass spectrometry has many different type of instruments, which can be broken up into two types; instruments that measures the chemistry of the particle ensemble (bulk measurement) and those that measure the chemistry of individual particles (single-particle measurement). Thus based on analytical need different instrumentation is used in analysis of the aerosol particles.
The word "aptamer" is a neologism coined by Andrew D. Ellington and Jack Szostak in their first publication on the topic. They did not provide a precise definition, stating "We have termed these individual RNA sequences 'aptamers', from the Latin aptus, to fit." The word itself, however, derives from the Greek word ἅπτω, to connect or fit (as used by Homer (c. 8th century BC)) and μέρος, a component of something larger. A typical aptamer is a synthetically generated ligand exploiting the combinatorial diversity of DNA, RNA, XNA, or peptide to achieve strong, specific binding for a particular target molecule or family of target molecules. Aptamers are occasionally classified as "chemical antibodies" or "antibody mimics". However, most aptamers are small, with a molecular weight of 6-30 kDa, in contrast to the 150 kDa size of antibodies, and contain one binding site rather than the two matching antigen binding regions of a typical antibody.
Amitriptyline was developed by the American pharmaceutical company Merck in the late 1950s. In 1958, Merck approached several clinical investigators proposing to conduct clinical trials of amitriptyline for schizophrenia. One of these researchers, Frank Ayd, instead, suggested using amitriptyline for depression. Ayd treated 130 patients and, in 1960, reported that amitriptyline had antidepressant properties similar to another, and the only known at the time, tricyclic antidepressant imipramine. Following this, the US Food and Drug Administration approved amitriptyline for depression in 1961. In Europe, due to a quirk of the patent law at the time allowing patents only on the chemical synthesis but not on the drug itself, Roche and Lundbeck were able to independently develop and market amitriptyline in the early 1960s. According to research by a historian of psychopharmacology David Healy, amitriptyline became a much bigger selling drug than its precursor imipramine because of two factors. First, amitriptyline has a much stronger anxiolytic effect. Second, Merck conducted a marketing campaign raising clinicians' awareness of depression as a clinical entity. Amitriptyline is no longer sold under the brand name Elavil.
Sources: en.wikipedia.org
The first tubeless automated insulin delivery system, Omnipod 5 uses SmartAdjust technology to actively predict glucose levels up to 60 minutes ahead and adjust insulin delivery every 5 minutes—automatically increasing, decreasing, or pausing basal insulin—towards a user‑customizable glucose target. The system integrates with several continuous glucose monitors: Dexcom G6, Dexcom G7, and Freestyle Libre 2 Plus. Omnipod 5 is FDA‑cleared for people with type 1 diabetes aged 2 years and older, and adults with type 2 diabetes aged 18+. The Omnipod 5 became available through the NHS in the UK in 2023 in limited areas, and in 2024 the NHS announced the gradual rollout of Hybrid Closed Loop systems to all type 1 diabetes patients in England over the next 5 years, including the Omnipod 5.
Newton has been a major driver in the PKC research field since the 1980s, working originally with Daniel E. Koshland Jr. She helped define the multiple different mechanisms of PKC regulation by phosphorylation and its interaction with specific membrane phospholipids, such as phosphatidylserine She has also made important discoveries in the protein phosphatase field, discovering and naming PHLPP (PH domain and Leucine rich repeat Protein Phosphatases), which regulate intracellular signaling through dephosphorylation of AKT. As of 2020, Newton has published over 190 peer-reviewed research articles that have been cited more than 25,000 times, been awarded 1 patent and co-edited two books on protein biochemistry and PKC. Her work straddles basic research and has illuminated understanding of PKC in Alzheimer's disease and as a tumor suppressor in human cancers
The European Aviation Safety Agency (EASA) is tasked by Article 15(4) of Regulation (EC) No 216/2008 of the European Parliament and of the Council of February 20, 2008, to provide an annual review of aviation safety. The Annual Safety Review presents statistics on European and worldwide civil aviation safety. Statistics are grouped according to type of operation, for instance, commercial air transport, and aircraft category, such as aeroplanes, helicopters, gliders, etc. The Agency has access to accident and statistical information collected by the International Civil Aviation Organization (ICAO). States are required, according to ICAO Annex 13, on Aircraft Accident and Incident Investigation, to report to ICAO information, on accidents and serious incidents to aircraft with a maximum certificated take-off mass (MTOM) over 2250 kg. Therefore, most statistics in this review concern aircraft above this mass. In addition to the ICAO data, a request was made to the EASA Member States to obtain light aircraft accident data. Furthermore, data on the operation of aircraft for commercial air transport were obtained from both ICAO and the NLR Air Transport Safety Institute.
Ectopic fat is the storage of triglycerides in tissues other than adipose tissue, that are supposed to contain only small amounts of fat, such as the liver, skeletal muscle, heart, and pancreas. This can interfere with cellular functions and hence organ function and is associated with insulin resistance in type 2 diabetes. It is stored in relatively high amounts around the organs of the abdominal cavity, but is not to be confused with visceral fat. The specific cause for the accumulation of ectopic fat is unknown. The cause is likely a combination of genetic, environmental, and behavioral factors that are involved in excess energy intake and decreased physical activity. Substantial weight loss can reduce ectopic fat stores in all organs and this is associated with an improvement of the function of those organs. In the latter case, non-invasive weight loss interventions like diet or exercise can decrease ectopic fat (particularly in heart and liver) in overweight or obese children and adults.
Sources: en.wikipedia.org
It is made from whey, the liquid byproduct of cheese or casein manufacture. The whey protein is treated with enzymes that cleave peptide bonds. The resulting mixture contains peptides of varying lengths plus some free amino acids.
Whey protein isolate is largely intact protein with a high protein content by dry weight. Hydrolysate has been enzymatically broken into smaller peptides, which can change taste, osmolality, and absorption behavior. Both can have similar total amino acid content, but their peptide profiles differ.
No. Hypoallergenic status depends on the extent of hydrolysis and the residual allergenic protein fragments. Regulatory bodies set specific criteria for products labeled hypoallergenic or extensively hydrolyzed. A hydrolysate not meeting those criteria may still contain allergenic epitopes.
Hydrolysis extent is commonly estimated by quantifying free amino groups or soluble nitrogen after protein cleavage. The result is expressed as a percentage of cleaved peptide bonds. Different assays use different definitions and may not agree exactly.